Non-neuroinvasive viruses and uses thereof
US-10647964-B2 · May 12, 2020 · US
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C12N2710/16632 |
| Official title | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent |
| Display label | Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent |
| Total patents | 168 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is growing.
| Year | Patents |
|---|---|
| 2015 | 8 |
| 2016 | 7 |
| 2017 | 11 |
| 2018 | 11 |
| 2019 | 20 |
| 2020 | 22 |
| 2021 | 18 |
| 2022 | 18 |
| 2023 | 15 |
| 2024 | 10 |
| 2025 | 23 |
| 2026 | 5 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Gut-protective effect of rig-1/mavs and sting activation
US-2020108091-A1 · Apr 9, 2020 · US
Expression of pten-long with ocolytic viruses
US-2020085890-A1 · Mar 19, 2020 · US
Compositions and methods for self-adjuvanting vaccines against microbes and tumors
US-10500271-B2 · Dec 10, 2019 · US
Herpesvirus with Modified Glycoprotein B
US-2019336551-A1 · Nov 7, 2019 · US
Oncolytic herpes simplex virus and therapeutic uses thereof
US-10456432-B2 · Oct 29, 2019 · US
Cancer Treatment and Diagnosis
US-2019314429-A1 · Oct 17, 2019 · US
Herpesvirus with Modified Glycoprotein D
US-2019309024-A1 · Oct 10, 2019 · US
Herpesvirus with Modified Glycoprotein H for Propagation in a Cell
US-2019300862-A1 · Oct 3, 2019 · US
Retargeted herpesvirus with a glycoprotein H fusion
US-10421979-B2 · Sep 24, 2019 · US
Oncolytic hsv vector
US-2019262410-A1 · Aug 29, 2019 · US
Methods of enhancing translation ability and stability of rna molecules, treatments, and kits
US-2019264214-A1 · Aug 29, 2019 · US
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
US-2019262473-A1 · Aug 29, 2019 · US
Polypeptides for improved response to anti-cancer therapy
US-2019255146-A1 · Aug 22, 2019 · US
Oncolytic hsv1 vectors and methods of using the same
US-2019160123-A1 · May 30, 2019 · US
Compositions and methods for treatment of muscular dystrophy
US-10286085-B2 · May 14, 2019 · US
Compositions and methods for self-adjuvanting vaccines against microbes and tumors
US-10265394-B2 · Apr 23, 2019 · US
Compositions and methods for self-adjuvanting vaccines against microbes and tumors
US-10238734-B2 · Mar 26, 2019 · US
Oncolytic HSV1 vectors and methods of using the same
US-10232002-B1 · Mar 19, 2019 · US
Hsv-1 oncolytic virus therapies that specifically kill alt dependent cancers
US-2019046594-A1 · Feb 14, 2019 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C12N2710/16632?
- CPC C12N2710/16632 is the Cooperative Patent Classification code for “Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent.”
- How many patents are filed under CPC C12N2710/16632 (Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent)?
- Our database includes 168 publications tagged with this CPC code.
- Is patent activity under CPC C12N2710/16632 growing?
- Publication counts under this code: 10 in 2024 vs 23 in 2025 (latest complete years).